Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
New to MyHealth?
Manage Your Care From Anywhere.
Access your health information from any device with MyHealth. You can message your clinic, view lab results, schedule an appointment, and pay your bill.
ALREADY HAVE AN ACCESS CODE?
DON'T HAVE AN ACCESS CODE?
NEED MORE DETAILS?
MyHealth for Mobile
Get the iPhone MyHealth app »
Get the Android MyHealth app »
Effect of Albiglutide, When Added to Standard Blood Glucose Lowering Therapies, on Major Cardiovascular Events in Subjects With Type 2 Diabetes Mellitus
Trial ID or NCT#
NCT02465515
Status
RECRUITING
Purpose
Albiglutide is an analogue of glucagon-like peptide-1 (GLP-1), used to treat type 2 diabetes.This study will test whether albiglutide affects the occurrence of major cardiovascular events such as heart attacks or strokes and other important medical outcomes in persons with type 2 diabetes, when used alone or added to other diabetes treatments.
Investigator(s)
Marilyn Tan, MD
Contact us to find out if this trial is right for you.
CONTACT
Stephanie Middleton
(650) 497-5532
View on ClinicalTrials.gov
About this Clinical Trial
Your Message Will Go To
Stephanie Middleton650-497-5532